Related Experiment Video
Updated: Feb 6, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials
Daniël H van Raalte1, David Z I Cherney2
1Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
Abstract:
Sodium glucose cotransporter 2 inhibitors are increasingly being recognized for renal protective effects that are largely independent of hemoglobin A1c-lowering or glucosuria-related endpoints. Accordingly, there is growing interest in potential renal benefits with sodium glucose cotransporter 2 inhibitors in nondiabetic patients to take advantage of natriuresis-mediated effects on blood pressure, proteinuria, and renal function. In this issue of Kidney International, Zhang et al. report renoprotective effects with the sodium glucose cotransporter 2 inhibitor lusogliflozin in an ischemia-reperfusion injury model under nondiabetic conditions, thereby providing important mechanistic insights into the use of these agents in chronic kidney disease.
Insights
Sodium glucose cotransporter 2 inhibitors show kidney protection beyond blood sugar control. Lusogliflozin demonstrated renoprotective effects in a nondiabetic model, suggesting benefits for chronic kidney disease.
Area of Science:
- Nephrology
- Pharmacology
Background:
- Sodium glucose cotransporter 2 (SGC2) inhibitors offer renal protection independent of glycemic control.
- Interest is growing in SGC2 inhibitors for nondiabetic kidney disease due to natriuresis-mediated effects.
- These effects include improvements in blood pressure, proteinuria, and renal function.
Purpose of the Study:
- To investigate the renoprotective effects of SGC2 inhibitors in nondiabetic conditions.
- To explore the mechanistic insights of lusogliflozin in a kidney injury model.
Main Methods:
- Utilized an ischemia-reperfusion injury model in nondiabetic subjects.
- Administered the SGC2 inhibitor lusogliflozin.
Main Results:
- Lusogliflozin exhibited significant renoprotective effects.
- These effects were observed under nondiabetic conditions, independent of glucose-lowering.
Conclusions:
- SGC2 inhibitors, like lusogliflozin, possess intrinsic renal protective properties.
- These findings support the potential utility of SGC2 inhibitors in managing chronic kidney disease, even in nondiabetic patients.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Statistical Software for Data Analysis and Clinical Trials
Feedback Inhibition
Trial and Error and Algorithm
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...

